http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2617516-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca5989f126acf2b6ec66e236150f2fff |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 |
| filingDate | 2016-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b97950e76b435fcf7e0607d12575e2ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f72d3f50ec37fea434a05dd1fc307703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_051e8f58e4c04575f24bfd1634011f2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6caeb97672dcb53766a179f5a1ab9a2 |
| publicationDate | 2017-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2617516-C1 |
| titleOfInvention | Method of treatment of infantile hemangiomas |
| abstract | FIELD: medicine. n SUBSTANCE: for the treatment of infantile hemangiomas with atenolol in children aged 1 month to 3 years old with infantile hemangiomas any form, in the active growth phase, prescribed atenolol at a dose of 0.5 to 1.0 mg/kg body weight of the child per day in 2 receiving the daily dose is divided into equal parts and give every 12 hours. Atenolol administered in two stages, the starting dose of 0.5 mg/kg/day, therapeutic dosage - 1.0 mg/kg/day, treatment of 4 to 6 months. And children from 1 month to 3 months of life, the recommended maximum dose of 0.5 mg/kg body weight, use of the drug on the ECG monitor and holterovsokom monitoring, the drug is prescribed after a cardiac examination, removal of the drug takes place gradually over a period of two weeks, at first, in the first week, atenolol administered at the rate of 50% of the therapeutic dosage in the second week, the drug is prescribed for 25% of the therapeutic dosage. The effectiveness of treatment was assessed a month from the date of the appointment, then every 2 months from the date of initiation of therapy. n EFFECT: blanching of the hemangioma and the reduction of its size. n 2 dwg, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2701213-C1 |
| priorityDate | 2016-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.